BR112015022993A8 - inibidores de jak2 e alk2 e métodos para sua utilização. - Google Patents

inibidores de jak2 e alk2 e métodos para sua utilização.

Info

Publication number
BR112015022993A8
BR112015022993A8 BR112015022993A BR112015022993A BR112015022993A8 BR 112015022993 A8 BR112015022993 A8 BR 112015022993A8 BR 112015022993 A BR112015022993 A BR 112015022993A BR 112015022993 A BR112015022993 A BR 112015022993A BR 112015022993 A8 BR112015022993 A8 BR 112015022993A8
Authority
BR
Brazil
Prior art keywords
jak2
methods
compounds
inhibitors
alk2
Prior art date
Application number
BR112015022993A
Other languages
English (en)
Other versions
BR112015022993B1 (pt
BR112015022993A2 (pt
Inventor
Mollard Alexis
J Bearss David
A Flynn Gary
Vankayalapati Hariprasad
L Warner Steven
Original Assignee
Tolero Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolero Pharmaceuticals Inc filed Critical Tolero Pharmaceuticals Inc
Publication of BR112015022993A2 publication Critical patent/BR112015022993A2/pt
Publication of BR112015022993A8 publication Critical patent/BR112015022993A8/pt
Publication of BR112015022993B1 publication Critical patent/BR112015022993B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

resumo “inibidores de jak2 e alk2 e métodos de uso dos mesmos” compostos que possuem atividade como inibidores da quinase alk2 e/ou quinase jak2 são revelados. os compostos têm a seguinte estrutura (i): incluindo estereoisômeros, tautômeros, os seus sais farmaceuticamente aceitáveis e pró-fármacos, em que r1, r2, r3, r4, r5, r6, r7, r8, x, z e a são co-mo aqui definidos. métodos associados com a preparação e utilização de tais com-postos, bem como composições farmacêuticas compreendendo tais compostos, são também descritos.
BR112015022993-0A 2013-03-14 2014-03-13 Inibidores de jak2 e alk2, composição farmacêutica compreendendo os referidos inibidores e uso destes BR112015022993B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785460P 2013-03-14 2013-03-14
US61/785,460 2013-03-14
PCT/US2014/026595 WO2014151871A2 (en) 2013-03-14 2014-03-13 Jak2 and alk2 inhibitors and methods for their use

Publications (3)

Publication Number Publication Date
BR112015022993A2 BR112015022993A2 (pt) 2017-07-18
BR112015022993A8 true BR112015022993A8 (pt) 2018-01-23
BR112015022993B1 BR112015022993B1 (pt) 2021-12-14

Family

ID=

Also Published As

Publication number Publication date
US20190119221A1 (en) 2019-04-25
IL277917A (en) 2020-11-30
DK2970205T3 (da) 2019-07-29
AU2020223731B2 (en) 2022-10-20
KR20160009017A (ko) 2016-01-25
ES2738493T3 (es) 2020-01-23
JP6703586B2 (ja) 2020-06-03
AU2018256624B2 (en) 2020-05-28
CN105308033B (zh) 2018-08-24
HK1218917A1 (zh) 2017-03-17
EP3590932B1 (en) 2023-05-03
AU2020223731A1 (en) 2020-09-17
WO2014151871A9 (en) 2014-12-31
JP2020125354A (ja) 2020-08-20
IL241194A0 (en) 2015-11-30
JP2019031569A (ja) 2019-02-28
CA2905993A1 (en) 2014-09-25
CN105308033A (zh) 2016-02-03
TR201911151T4 (tr) 2019-08-21
RU2019119893A (ru) 2019-08-09
WO2014151871A3 (en) 2014-12-04
US20160214944A1 (en) 2016-07-28
IL241194B (en) 2019-06-30
US10752594B2 (en) 2020-08-25
BR112015022993A2 (pt) 2017-07-18
AU2014236820B2 (en) 2018-08-02
EP3590932A1 (en) 2020-01-08
CN108997225A (zh) 2018-12-14
MX2021008356A (es) 2021-10-13
IL267161B (en) 2020-10-29
IL267161A (en) 2019-08-29
JP2016513661A (ja) 2016-05-16
KR102334260B1 (ko) 2021-12-02
IL277917B (en) 2022-01-01
JP6433974B2 (ja) 2018-12-05
MX2015012062A (es) 2016-05-05
CA2905993C (en) 2022-12-06
US20240083855A1 (en) 2024-03-14
AU2018256624A1 (en) 2018-11-22
EP2970205B1 (en) 2019-05-08
PL2970205T3 (pl) 2019-10-31
AU2014236820A1 (en) 2015-10-01
RU2693480C2 (ru) 2019-07-03
RU2015143542A (ru) 2017-04-19
KR20210149232A (ko) 2021-12-08
US20210070715A1 (en) 2021-03-11
PT2970205T (pt) 2019-08-26
US10202356B2 (en) 2019-02-12
WO2014151871A2 (en) 2014-09-25
EP2970205A2 (en) 2016-01-20
HUE044558T2 (hu) 2019-11-28

Similar Documents

Publication Publication Date Title
TR201911151T4 (tr) Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
BR112014033080A2 (pt) inibidores do vírus da hepatite c
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112018076169A2 (pt) derivados azabenzimidazol como inibidores de pi3k beta
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
CO6680717A2 (es) Derivados de quinolina y quinoxalina como inhibidores de cinasa
MX2015012850A (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
BR112014030685A2 (pt) compostos de n-alquiltriazol como antagonistas de lpar
BR112015022804A2 (pt) novos derivados de octahidro-pirrol [3,4-c]-pirrol e seus análogos como inibidores de autotaxina
BR112018071216A2 (pt) inibidores de bromodomínios
CO6751270A2 (es) Compuestos y composiciones como inhibidores de la trk
NI201400150A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
MY165584A (en) Ampk-activating heterocyclic compounds and methods for using the same
TN2016000017A1 (en) Piperidinyl indole derivatives and their use as complement factor b inhibitors
BR112016014760A2 (pt) composto, composição farmacêutica, métodos para tratamento de uma condição, para inibir e validar atividade de cinase, para modular o trajeto de b-catenina e o trajeto de tgfb/bmp em uma célula, para modular a atividade de stat1 e de hif-1-alfa em uma célula, para aumentar a expressão de bim e para preparar um composto, mutante, e, proteína
BR112014013974A8 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112016029612A2 (pt) compostos de di-hidroisoquinolinona substituídos
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
BR112014010407A2 (pt) compostos de azetidina, composições e seu uso como inibidores de hidrolase de epóxido solúvel
BR112015018087A8 (pt) composto, composição farmacêutica e uso
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112014027117A8 (pt) Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
BR112017023038A2 (pt) imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: BOSTON BIOMEDICAL, INC. (US)

B25D Requested change of name of applicant approved

Owner name: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/03/2014, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: SUMITOMO PHARMA ONCOLOGY, INC. (US)

B25G Requested change of headquarter approved

Owner name: SUMITOMO PHARMA ONCOLOGY, INC. (US)